Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95738 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2735604 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2352413 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL2351564 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11753530 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL27965 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11032494 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL11518271 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8846723 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL95500 | 1.00 | LMNA (0.68) | LMNABLMPTPN1ALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | claimed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | claimed |
| US-9464021-B2 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP S (IN) | 2016-10-11 | — | — | US | disclosed |
| US-9464021-B2 | Method of preparation of stereospecific quinone derivatives | MEHTA DILIP S (IN) | 2016-10-11 | — | — | US | disclosed |
| US-20150126763-A1 | METHOD OF PREPARATION OF STEREOSPECIFIC QUINONE DERIVATIVES | MEHTA DILIP S (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150126763-A1 | METHOD OF PREPARATION OF STEREOSPECIFIC QUINONE DERIVATIVES | MEHTA DILIP S (IN) | 2015-05-07 | — | — | US | disclosed |
| US-8426617-B2 | Asymmetric hydrogenation of alkenes using chiral iridium complexes | DSM IP ASSETS B.V. (NL) | 2013-04-23 | — | — | US | disclosed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | disclosed |
| WO-2008045555-A9 | FUEL COMPOSITIONS COMPRISING FARNESANE AND FARNESANE DERIVATIVES AND METHOD OF MAKING AND USING SAME | AMYRIS BIOTECHNOLOGIES INC (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008045555-A2 | FUEL COMPOSITIONS COMPRISING FARNESANE AND FARNESANE DERIVATIVES AND METHOD OF MAKING AND USING SAME | AMYRIS BIOTECHNOLOGIES, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | disclosed |
| US-4151360-A | Optically active amine salts | HOFFMANN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4138289-A | ASYMMETRIC HYDROGENATION BY MICROORGANISM, FERMENTATION | HOFFMANN-LA ROCHE INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4102909-A | Optically active esters and amides | HOFFMANN-LA ROCHE INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4094892-A | CLAISEN REARRANGEMENT | HOFFMANN-LA ROCHE INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4045475-A | Optically active alcohols and lower esters thereof | HOFFMANN-LA ROCHE INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4026907-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4018799-A | INTERMEDIATES FOR TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4003919-A | INTERMEDIATES FOR ALPHA-TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3947473-A | (6-HYDROXY-CHROMAN-2-YL) CARBOXYLIC ACID DERIVATIVES | HOFFMAN-LA ROCHE INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126763-A1 | METHOD OF PREPARATION OF STEREOSPECIFIC QUINONE DERIVATIVES | UBE2D3, ULK3, UCK2 | LMNA 1773/4885BLM 1822/4885PTPN1 4709/4885 |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | LMNA 4536/4885BLM 3337/4885PTPN1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.